# EDGAR Filing Document

**Accession Number:** 0000879407
**File Stem:** 0001193125-26-212473
**Filing Date:** 2026-5
**Character Count:** 16879
**Document Hash:** 9cb4ca38f1d061b0bd3d1a5637ef4f07
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-212473.hdr.sgml**: 20260507

**ACCESSION NUMBER**: 0001193125-26-212473

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 14

**FILED AS OF DATE**: 20260507

**DATE AS OF CHANGE**: 20260507

**EFFECTIVENESS DATE**: 20260507

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ARROWHEAD PHARMACEUTICALS, INC.
- **CENTRAL INDEX KEY:** 0000879407
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 460408024
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-295670
- **FILM NUMBER:** 26955001

**BUSINESS ADDRESS:**
- **STREET 1:** 177 E COLORADO BLVD
- **STREET 2:** SUITE 700
- **CITY:** PASADENA
- **STATE:** CA
- **ZIP:** 91105
- **BUSINESS PHONE:** 626-696-4702

**MAIL ADDRESS:**
- **STREET 1:** 177 E COLORADO BLVD
- **STREET 2:** SUITE 700
- **CITY:** PASADENA
- **STATE:** CA
- **ZIP:** 91105

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ARROWHEAD RESEARCH CORP
- **DATE OF NAME CHANGE:** 20040112

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** INTERACTIVE GROUP INC
- **DATE OF NAME CHANGE:** 20020509

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** INTERACTIVE INC
- **DATE OF NAME CHANGE:** 19940224

**As filed with the Securities and Exchange Commission on May 7, 2026** 

**Registration No. 333-** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**WASHINGTON, D.C. 20549** 

**FORM S-8** 

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

## ARROWHEAD PHARMACEUTICALS, INC.
**(Exact Name of Registrant as Specified in its Charter)** 

---

| | |
|:---|:---|
| **Delaware** | **46-0408024** |
| **(State or Other Jurisdiction of<br>Incorporation or Organization)** | **(I.R.S. Employer<br>Identification No.)** |

---

**177 E. Colorado Blvd, Suite 700** 

**Pasadena, CA 91105** 

**(Address of Principal Executive Offices)** 

**ARROWHEAD PHARMACEUTICALS, INC. AMENDED AND RESTATED 2021 INCENTIVE PLAN** 

**ARROWHEAD PHARMACEUTICALS, INC. AMENDED AND RESTATED INDUCEMENT PLAN** 

**(Full Title of the Plan)** 

**Christopher Anzalone** 

**President and Chief Executive Officer** 

**177 E. Colorado Blvd, Suite 700** 

**Pasadena, CA 91105** 

**Telephone: (626) 304-3400** 

**(Name, address, and telephone number, including area code, of agent for service)** 

***Copy to:***

**Ryan A. Murr** 

**Gibson, Dunn & Crutcher LLP** 

**One Embarcadero Center, Suite 2600** 

**San Francisco, California 94111** 

**Telephone: (415) 393-8200** 

**Facsimile: (415) 393-8306** 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☒ | Accelerated filer | ☐ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
| Emerging growth company | ☐ |  |  |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**Introduction** 

This registration statement on Form S-8 (this "Registration Statement") is being filed by Arrowhead Pharmaceuticals, Inc. (the "Registrant") to register a total of 12,667,050 shares of Common Stock, par value $0.001 per share ("Common Stock"), which includes (i) 10,500,000 shares of Common Stock issuable under the Arrowhead Pharmaceuticals, Inc. Amended and Restated 2021 Incentive Plan, and (ii) 2,167,050 shares of Common Stock issuable under the Arrowhead Pharmaceuticals, Inc. Amended and Restated Inducement Plan.

Pursuant to General Instruction E of Form S-8, the information contained in the Registrant's registration statements on Form S-8 filed on May 18, 2021 ([File No. 333-256255](http://www.sec.gov/Archives/edgar/data/879407/000119312521165331/d512029ds8.htm)) and February 28, 2024 ([File No. 333-277477](http://www.sec.gov/Archives/edgar/data/879407/000162828024007674/arwrforms-8inducementplanf.htm)), together with all exhibits filed therewith or incorporated therein by reference, is hereby incorporated by reference and made a part hereof, except for those items being updated by this Registration Statement.

------

**Item 8. Exhibits** 

---

| | |
|:---|:---|
| **Exhibit<br>No.** | **Description** |
| &nbsp;&nbsp;&nbsp;&nbsp;4.1 | [Amended and Restated Certificate of Incorporation of Arrowhead Pharmaceuticals, Inc. (1)](http://www.sec.gov/Archives/edgar/data/879407/000119312516532364/d175317dex33.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;4.2 | [Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Arrowhead Pharmaceuticals, Inc. (2)](http://www.sec.gov/Archives/edgar/data/879407/000162828023014856/arrowheadpharmaceuticals.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;4.3 | [Second Amended and Restated Bylaws of Arrowhead Pharmaceuticals, Inc. (3)](http://www.sec.gov/Archives/edgar/data/879407/000162828023002413/exhibit32.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;5.1 | [Opinion of Gibson, Dunn & Crutcher LLP\*](d30467dex51.htm) |
| 23.1 | [Consent of KPMG LLP\*](d30467dex231.htm) |
| 23.2 | [Consent of Gibson, Dunn & Crutcher LLP (filed as a part of Exhibit 5.1)\*](d30467dex51.htm) |
| 24.1 | [Power of Attorney (set forth on signature page of this Registration Statement)\*](d30467ds8.htm#sig) |
| 99.1 | [Arrowhead Pharmaceuticals, Inc. Amended and Restated 2021 Incentive Plan (4)](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/879407/000087940726000019/arwr-20260126.htm) |
| 99.2 | [Arrowhead Pharmaceuticals, Inc. Amended and Restated Inducement Plan (5)](http://www.sec.gov/Archives/edgar/data/879407/000087940726000047/exhibit102amendedandrest.htm) |
| 107.1 | [Calculation of Filing Fee Table\*](d30467dexfilingfees.htm) |

---

\* Filed herewith.

(1) Filed as Exhibit 3.3 to the Registrant's Current Report on Form 8-K, filed on April 6, 2016 and incorporated herein by reference.

(2) Filed as Exhibit 3.2 to the Registrant's Quarterly Report on Form 10-Q, filed on May 2, 2023 and incorporated herein by reference.

(3) Filed as Exhibit 3.1 to the Registrant's Current Report on Form 8-K, filed on January 30, 2023 and incorporated herein by reference.

(4) Filed as Exhibit A to the Registrant's Proxy Statement on Schedule DEF 14A, filed on January 27, 2026,
and incorporated herein by reference.

(5) Filed as Exhibit 10.2 to the Registrant's Quarterly Report on Form 10-Q, filed on May 7, 2026 and incorporated herein by reference.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, as amended (the "Securities Act"), the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Pasadena, California, on May 7, 2026.

---

| | |
|:---|:---|
| **Arrowhead Pharmaceuticals, Inc.** | **Arrowhead Pharmaceuticals, Inc.** |
| By: | /s/ Christopher Anzalone |
|  | Christopher Anzalone |
|  | President and Chief Executive Officer |

---

**POWER OF ATTORNEY** 

Each of the undersigned hereby constitutes and appoints each of Christopher Anzalone and Daniel Apel, his or her attorney-in-fact, with power of substitution, in his or her name and in the capacity indicated below, to sign any and all further amendments (including post-effective amendments) to this Registration Statement and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that said attorney-in-fact, or his substitute or substitutes, may do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| Signature | Title | Date |
| /s/ Christopher Anzalone<br> Christopher Anzalone | President, Chief Executive Officer and Director (Principal Executive Officer) | May 7, 2026 |
| /s/ Daniel Apel<br> Daniel Apel | Chief Financial Officer<br> (Principal Financial and Accounting Officer) | May 7, 2026 |
| /s/ Mauro Ferrari<br> Mauro Ferrari | Director | May 7, 2026 |
| /s/ Hongbo Lu<br> Hongbo Lu | Director | May 7, 2026 |
| /s/ Adeoye Olukotun<br> Adeoye Olukotun | Director | May 7, 2026 |
| /s/ Michael S. Perry<br> Michael S. Perry | Director | May 7, 2026 |
| /s/ Victoria Vakiener<br> Victoria Vakiener | Director | May 7, 2026 |
| /s/ William Waddill<br> William Waddill | Director | May 7, 2026 |

---

## Exhibit 5.1

**Exhibit 5.1**![LOGO](g30467g0505080541146.jpg)

May 7, 2026

Arrowhead Pharmaceuticals, Inc.

177 E. Colorado Blvd, Suite 700

Pasadena, CA 91105

Re: *Arrowhead Pharmaceuticals, Inc.*

*Registration Statement on Form S-8* 

Ladies and Gentlemen:

We have examined the Registration Statement on Form S-8 (the "Registration Statement") of Arrowhead Pharmaceuticals, Inc., a Delaware corporation (the "Company"), to be filed with the Securities and Exchange Commission (the "Commission") pursuant to the Securities Act of 1933, as amended (the "Securities Act"), in connection with the offering by the Company of up to 12,667,050 shares of the Company's Common Stock, par value $0.001 per share (the "Shares"). The Shares subject to the Registration Statement are to be issued under the Arrowhead Pharmaceuticals, Inc. Amended and Restated 2021 Incentive Plan and the Arrowhead Pharmaceuticals, Inc. Amended and Restated Inducement Plan (collectively, the "Plans").

We have examined the originals, or photostatic or certified copies, of such records of the Company and certificates of officers of the Company and of public officials and such other documents as we have deemed relevant and necessary as the basis for the opinions set forth below. In our examination, we have assumed the genuineness of all signatures, the legal capacity and competency of all natural persons, the authenticity of all documents submitted to us as originals and the conformity to original documents of all documents submitted to us as copies. We have also assumed that there are no agreements or understandings between or among the Company and any participants in the Plans that would expand, modify or otherwise affect the terms of the Plans or the respective rights or obligations of the participants thereunder. Finally, we have assumed the accuracy of all other information provided to us by the Company during the course of our investigations, on which we have relied in issuing the opinion expressed below.

Based upon the foregoing examination and in reliance thereon, and subject to the qualifications, assumptions and limitations stated herein and in reliance on the statements of fact contained in the documents that we have examined, we are of the opinion that the Shares, when issued and sold in accordance with the terms set forth in the applicable Plan and against payment therefor, and when the Registration Statement has become effective under the Securities Act, will be validly issued, fully paid and non-assessable.

**Gibson, Dunn & Crutcher LLP** 

One Embarcadero Center Suite 2600 \| San Francisco, CA 94111-3715 \| T: Tel 415.393.8200 \| F: 415.393.8306 \| gibsondunn.com

------

![LOGO](g30467g0505080541146.jpg)

Arrowhead Pharmaceuticals, Inc.

May 7, 2026

We render no opinion herein as to matters involving the laws of any jurisdiction other than the Delaware General Corporation Law (the "DGCL"). We are not admitted to practice in the State of Delaware; however, we are generally familiar with the DGCL as currently in effect and have made such inquiries as we consider necessary to render the opinions above. This opinion is limited to the effect of the current state of the DGCL and the facts as they currently exist. We assume no obligation to revise or supplement this opinion in the event of future changes in such law or the interpretations thereof or such facts.

We consent to the filing of this opinion as an exhibit to the Registration Statement. In giving these consents, we do not thereby admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the Rules and Regulations of the Commission.

---

| |
|:---|
|  Very truly yours, |
|  /s/ Gibson, Dunn & Crutcher LLP |

---

## Exhibit 23.1

**Exhibit 23.1** 

**Consent of Independent Registered Public Accounting Firm** 

We consent to the use of our reports dated November 25, 2025, with respect to the consolidated financial statements of Arrowhead Pharmaceuticals, Inc. and subsidiaries, and the effectiveness of internal control over financial reporting, incorporated herein by reference.

/s/ KPMG LLP

San Diego, California

May 7, 2026

KPMG LLP, a Delaware limited liability partnership, and its subsidiaries are part of

the KPMG global organization of independent member firms affiliated with KPMG

International Limited, a private English company limited by guarantee.

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**ARROWHEAD PHARMACEUTICALS, INC.**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Security Type**  | **Security Class Title**  | **Fee Calculation Rule**  | **Amount Registered**  | **Proposed Maximum Offering Price Per Unit**  | **Maximum Aggregate Offering Price**  | **Fee Rate**  | **Amount of Registration Fee**  |
| 1 | Equity | Common stock, par value $0.001 per share ("Common Stock") to be issued under the Arrowhead Pharmaceuticals, Inc. Amended and Restated 2021 Incentive Plan (the "2021 Plan") | 457(a) | 10500000 | $74.38 | $780990000.00 | 0.0001381 | $107854.72 |
| 2 | Equity | Common Stock to be issued under the Arrowhead Pharmaceuticals, Inc. Amended and Restated Inducement Plan (the "Inducement Plan") | 457(a) | 2167050 | $74.38 | $161185179.00 | 0.0001381 | $22259.67 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $942175179.00  |  | $130114.39  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $130114.39  |

---

 **Offering Note** <br>

<sup>1</sup> Pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement also covers any additional shares of Common Stock that become issuable by reason of any stock split, stock dividend or similar transaction effected without the receipt of consideration which results in an increase in the number of the registrant's outstanding shares of Common Stock. The "Amount Registered" represents shares of Common Stock issuable under the 2021 Plan. The "Proposed Maximum Offering Price Per Unit" and the "Maximum Aggregate Offering Price" are estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) and Rule 457(h) under the Securities Act, and are based on the average of the high and low sale prices of the registrant's Common Stock as reported on the Nasdaq Global Select Market on May 1, 2026.

<sup>2</sup> Pursuant to Rule 416 under the Securities Act, this registration statement also covers any additional shares of Common Stock that become issuable by reason of any stock split, stock dividend or similar transaction effected without the receipt of consideration which results in an increase in the number of the registrant's outstanding shares of Common Stock. The "Amount Registered" represents shares of Common Stock issuable under the Inducement Plan. The "Proposed Maximum Offering Price Per Unit" and the "Maximum Aggregate Offering Price" are estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) and Rule 457(h) under the Securities Act, and are based on the average of the high and low sale prices of the registrant's Common Stock as reported on the Nasdaq Global Select Market on May 1, 2026.

---

| |
|:---|
| |
| **Rule 457(p)** |
| Fee Offset Claims |
| Fee Offset Sources |

---